SCHEMBL5872049

SCHEMBL5872049

COC(=O)C(Cc1c[c]ccc1)C(=O)OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRB P23467 1/20 0.49
PPARG P37231 5/20 0.44
PPARD Q03181 4/20 0.44
PPARA Q07869 3/20 0.44
MMP8 P22894 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.38
CA12 O43570 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
ALDH1A1 P00352 1/20 0.38
THRB P10828 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 1/20 0.38
POLB P06746 2/20 0.37
ANPEP P15144 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5871840 0.80 PTPRB (0.54) PTPRBPPARGPPARDPPARAMMP8
SCHEMBL1442737 0.79 MMP8 (0.58) PTPRBPPARGPPARDPPARAMMP8
SCHEMBL3825446 0.75 KMT2A (0.31) KMT2A
SCHEMBL2642315 0.75 CYP4F2 (0.47) KMT2ACA12CA7CA9CA14
SCHEMBL8287672 0.74 PPARG (0.61) PTPRBPPARGPPARDPPARAMMP8
SCHEMBL391783 0.74 PPARG (0.61) PTPRBPPARGPPARDPPARAMMP8
SCHEMBL27808291 0.74 PPARG (0.53) PPARGPPARAMEN1KMT2AATM
SCHEMBL7956117 0.73 TBXAS1 (0.47) MEN1KMT2AHSD17B10POLBMAPT
SCHEMBL7270701 0.73 MMP8 (0.55) PTPRBPPARGPPARDPPARAMMP8
SCHEMBL27770370 0.73 TAAR1 (0.35) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071187-B2 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2006-07-04 US disclosed
US-20040214853-A1 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-10-28 US disclosed
EP-1426374-A1 NAPHTHYRIDINE DERIVATIVE OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214853-A1 Naphthyridine derivatives MT-ND1, OPRD1, NR0B1 PTPRB 3070/4885PPARG 1417/4885PPARD 452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.